Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Alice Giotta Lucifero & Sabino Luzzi. (2022) Emerging immune-based technologies for high-grade gliomas. Expert Review of Anticancer Therapy 22:9, pages 957-980.
Read now
Read now
Anne Clavreul, Milad Pourbaghi-Masouleh, Emilie Roger & Philippe Menei. (2019) Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far. International Journal of Nanomedicine 14, pages 2497-2513.
Read now
Read now
Articles from other publishers (34)
Debo Yun, Jianshen Liang, Xuya Wang, Jikang Fan, Xisen Wang, Jiabo Li, Xiao Ren, Jie Liu, Xiude Ren, Hao Zhang, Guanjie Shang, Wenzhe Jin, Lei Chen, Tao Li, Chen Zhang, Shengping Yu & Xuejun Yang. (2023) TCAF2 drives glioma cellular migratory/invasion properties through STAT3 signaling. Molecular and Cellular Biochemistry.
Crossref
Crossref
Minjie Fu, Zhirui Zhou, Xiao Huang, Zhenchao Chen, Licheng Zhang, Jinsen Zhang, Wei Hua & Ying Mao. (2023) Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map. BMC Cancer 23:1.
Crossref
Crossref
Qiaoyun Zhang, Guangheng Wu, Xiaoyu Zhang, Jie Zhang, Mengyang Jiang, Yiqiang Zhang, Lixiang Ding & Youxin Wang. (2023) Vascular endothelial growth factor and risk of malignant brain tumor: A genetic correlation and two-sample Mendelian randomization study. Frontiers in Oncology 13.
Crossref
Crossref
Mustafa Khasraw, Yoko Fujita, Catalina Lee-ChangIrina V. BalyasnikovaHinda NajemAmy B. Heimberger. (2022) New Approaches to Glioblastoma. Annual Review of Medicine 73:1, pages 279-292.
Crossref
Crossref
Hyrije Ademi, Dheeraj A. Shinde, Max Gassmann, Daniela Gerst, Hassan Chaachouay, Johannes Vogel & Thomas A. Gorr. (2021) Targeting neovascularization and respiration of tumor grafts grown on chick embryo chorioallantoic membranes. PLOS ONE 16:5, pages e0251765.
Crossref
Crossref
Alice Giotta Lucifero & Sabino Luzzi. (2021) Against the Resilience of High-Grade Gliomas: The Immunotherapeutic Approach (Part I). Brain Sciences 11:3, pages 386.
Crossref
Crossref
Shigeru YAMAGUCHI, Yukitomo ISHI, Hiroaki MOTEGI, Michinari OKAMOTO, Hiroyuki KOBAYASHI, Kenji HIRATA, Yoshitaka ODA, Shinya TANAKA, Shunsuke TERASAKA & Kiyohiro HOUKIN. (2021) The prognostic improvement of add-on bevacizumab for progressive disease during concomitant temozolomide and radiation therapy in patients with glioblastoma and anaplastic astrocytoma. Journal of Neurosurgical Sciences 64:6.
Crossref
Crossref
Ali Syed Arbab. 2021. New Targeting in the Reversal of Resistant Glioblastomas. New Targeting in the Reversal of Resistant Glioblastomas
1
7
.
Arata Tomiyama. 2021. Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies. Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies
547
585
.
Harman Saman, Syed Shadab Raza, Shahab Uddin & Kakil Rasul. (2020) Inducing Angiogenesis, a Key Step in Cancer Vascularization, and Treatment Approaches. Cancers 12:5, pages 1172.
Crossref
Crossref
Xin Mei, Yin‐Sheng Chen, Qing‐Ping Zhang, Fu‐Rong Chen, Shao‐Yan Xi, Ya‐Kang Long, Ji Zhang, Hai‐Ping Cai, Chao Ke, Jing Wang & Zhong‐Ping Chen. (2020) Association between glioblastoma cell‐derived vessels and poor prognosis of the patients. Cancer Communications 40:5, pages 211-221.
Crossref
Crossref
Elizabeth A. Kuczynski & Andrew R. Reynolds. (2019) Vessel co-option and resistance to anti-angiogenic therapy. Angiogenesis 23:1, pages 55-74.
Crossref
Crossref
Elizabeth A. Kuczynski, Peter B. Vermeulen, Francesco Pezzella, Robert S. Kerbel & Andrew R. Reynolds. (2019) Vessel co-option in cancer. Nature Reviews Clinical Oncology 16:8, pages 469-493.
Crossref
Crossref
Chenyue Xu, Luning Mao, Ji Xiong, Jianbo Wen, Yin Wang, Daoying Geng & Ying Liu. (2019) TAZ Expression on Endothelial Cells Is Closely Related to Blood Vascular Density and VEGFR2 Expression in Astrocytomas. Journal of Neuropathology & Experimental Neurology 78:2, pages 172-180.
Crossref
Crossref
Timo A. Auer, Hanns-Christian Breit, Federico Marini, Mirjam Renovanz, Florian Ringel, Clemens J. Sommer, Marc A. Brockmann & Yasemin Tanyildizi. (2019) Evaluation of the apparent diffusion coefficient in patients with recurrent glioblastoma under treatment with bevacizumab with radiographic pseudoresponse. Journal of Neuroradiology 46:1, pages 36-43.
Crossref
Crossref
Malaka Ameratunga, Niamh Coleman, Liam Welsh, Frank Saran & Juanita Lopez. (2018) CNS cancer immunity cycle and strategies to target this for glioblastoma. Oncotarget 9:32, pages 22802-22816.
Crossref
Crossref
J. Attal, L. Chaltiel, V. Lubrano, J. C. Sol, C. Lanaspeze, L. Vieillevigne, I. Latorzeff & E. Cohen-Jonathan Moyal. (2017) Subventricular zone involvement at recurrence is a strong predictive factor of outcome following high grade glioma reirradiation. Journal of Neuro-Oncology 136:2, pages 413-419.
Crossref
Crossref
Martin J. Hicks, Maria J. Chiuchiolo, Douglas Ballon, Jonathan P. Dyke, Eric Aronowitz, Kosuke Funato, Viviane Tabar, David Havlicek, Fan Fan, Dolan Sondhi, Stephen M. Kaminsky & Ronald G. Crystal. (2016) Anti-Epidermal Growth Factor Receptor Gene Therapy for Glioblastoma. PLOS ONE 11:10, pages e0162978.
Crossref
Crossref
Yuji Piao, Soon Young Park, Verlene Henry, Bryan D. Smith, Ningyi Tiao, Daniel L. Flynn & John F. de Groot. (2016) Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models. Neuro-Oncology 18:9, pages 1230-1241.
Crossref
Crossref
Jiahao Su, Meiqin Cai, Wensheng Li, Bo Hou, Haiyong He, Cong Ling, Tengchao Huang, Huijiao Liu & Ying Guo. (2016) Molecularly Targeted Drugs Plus Radiotherapy and Temozolomide Treatment for Newly Diagnosed Glioblastoma: A Meta-Analysis and Systematic Review. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 24:2, pages 117-128.
Crossref
Crossref
M. Ameratunga, G. McArthur, H. Gan & L. Cher. (2016) Prolonged disease control with MEK inhibitor in neurofibromatosis type I-associated glioblastoma. Journal of Clinical Pharmacy and Therapeutics 41:3, pages 357-359.
Crossref
Crossref
Mee Jeong Lee. (2016) Overview of CNS Gliomas in Childhood. Clinical Pediatric Hematology-Oncology 23:1, pages 8-16.
Crossref
Crossref
Jing Yu, Min Wang, Jiacheng Song, DongYa Huang & Xunning Hong. (2016) Potential Utility of Visually AcceSAble Rembrandt Images Assessment in Brain Astrocytoma Grading. Journal of Computer Assisted Tomography 40:2, pages 301-306.
Crossref
Crossref
Francesca Piludu, Simona Marzi, Andrea Pace, Veronica Villani, Alessandra Fabi, Carmine Maria Carapella, Irene Terrenato, Anna Antenucci & Antonello Vidiri. (2015) Early biomarkers from dynamic contrast-enhanced magnetic resonance imaging to predict the response to antiangiogenic therapy in high-grade gliomas. Neuroradiology 57:12, pages 1269-1280.
Crossref
Crossref
Xin Yang, Qiu-Feng Dong, Li-Wen Li, Jun-Li Huo, Peng-Qi Li, Zhou Fei & Hai-Ning Zhen. (2015) The cap-translation inhibitor 4EGI-1 induces mitochondrial dysfunction via regulation of mitochondrial dynamic proteins in human glioma U251 cells. Neurochemistry International 90, pages 98-106.
Crossref
Crossref
Guido Frosina. (2015) Limited advances in therapy of glioblastoma trigger re-consideration of research policy. Critical Reviews in Oncology/Hematology 96:2, pages 257-261.
Crossref
Crossref
Xiaoqing Li, Rongzhong Huang & Zhongye Xu. (2015) Risk of Adverse Vascular Events in Newly Diagnosed Glioblastoma Multiforme Patients Treated with Bevacizumab: a Systematic Review and Meta-Analysis. Scientific Reports 5:1.
Crossref
Crossref
Karrie Kiang, Xiao-Qin Zhang & Gilberto Leung. (2015) Long Non-Coding RNAs: The Key Players in Glioma Pathogenesis. Cancers 7:3, pages 1406-1424.
Crossref
Crossref
Lei Cao, Hui Lei, Ming-Ze Chang, Zhi-Qin Liu & Xiao-Hua Bie. (2015) Down-regulation of 14-3-3β exerts anti-cancer effects through inducing ER stress in human glioma U87 cells: Involvement of CHOP–Wnt pathway. Biochemical and Biophysical Research Communications 462:4, pages 389-395.
Crossref
Crossref
Antonio José Conde-Moreno, Raquel García-Gómez, María Albert-Antequera, Piedad Almendros-Blanco, Ramón De Las Peñas-Bataller, Verónica González-Vidal, José Luis López-Torrecilla & Carlos Ferrer-Albiach. (2015) Fractionated stereotactic radiotherapy plus bevacizumab after response to bevacizumab plus irinotecan as a rescue treatment for high-grade gliomas. Reports of Practical Oncology & Radiotherapy 20:3, pages 231-238.
Crossref
Crossref
Mao-Bin Meng, Nicholas G Zaorsky, Lei Deng, Huan-Huan Wang, Jiang Chao, Lu-Jun Zhao, Zhi-Yong Yuan & Wang Ping. (2015) Pericytes: a double-edged sword in cancer therapy. Future Oncology 11:1, pages 169-179.
Crossref
Crossref
Bruce C Baguley & Mark J McKeage. (2014) Therapeutic targeting of tumor angiogenesis: how far have we come?. Clinical Investigation 4:12, pages 1113-1122.
Crossref
Crossref
Jenny Adamski, Uri Tabori & Eric Bouffet. (2014) Advances in the Management of Paediatric High-Grade Glioma. Current Oncology Reports 16:12.
Crossref
Crossref
Guangzhi Gu, Quanyin Hu, Xingye Feng, Xiaoling Gao, Jiang Menglin, Ting Kang, Di Jiang, Qingxiang Song, Hongzhuan Chen & Jun Chen. (2014) PEG-PLA nanoparticles modified with APTEDB peptide for enhanced anti-angiogenic and anti-glioma therapy. Biomaterials 35:28, pages 8215-8226.
Crossref
Crossref